Skip to content

Dark Halo and MNV: a Study Between ICGA and OCTA

Dark Halo a New Biomarker in Macular Neovascularization: a Comparative Study Between ICGA and OCTA

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05108285
Enrollment
50
Registered
2021-11-04
Start date
2018-01-01
Completion date
2020-12-15
Last updated
2021-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Macular Neovascularisation

Brief summary

The aim of study is to compare the evaluation of dark halo area of macular neovascularization (MNV) between indocyanine green angiography (ICGA) and optical coherence tomography angiography (OCTA) in order to identify OCTA as effective and useful biomarker in MNV

Detailed description

Dark halo is defined as a dark perilesional of flow decrease due to an area of reduced choroidal flow adjacent to the macular neovascularization (MNV). The detection of MNV vascular details was only possible through invasive dye injection, such as fluorescein angiography (FA) or indocyanine green angiography (ICGA). Optical coherence tomography angiography (OCTA) is a recent imaging technique that is able to detect the perfusion and non-perfusion areas carefully. The aim of study is to compare the evaluation of dark halo area of MNV between ICGA and OCTA

Interventions

DIAGNOSTIC_TESTOptical Coherence Tomography Angiography (OCTA) and indocyanine green angiography (ICGA)

OCTA and ICGA is able to detect the dark halo as a area of reduced perfusion around MVN

Sponsors

Federico II University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
55 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* age older than 55 years * diagnosis of macular neovascularization * absence of previous treatment with anti-Vegf injections * absence of other retinal vascular diseases

Exclusion criteria

* age younger than 55 years * absence diagnosis of macular neovascularization * presence of previous treatment with anti-Vegf injections * presence of other retinal vascular diseases

Design outcomes

Primary

MeasureTime frameDescription
Dark halo measurementthree yearsThe OCTA and ICGA parameters analyzed are: the area of dark halo (mm2) that surrounds the coroidal neovascularization.

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026